3nd Quarter Report

Third Quarter 2019 Report

October 18, 2019

OneTest Quarterly Volume More than Doubles

For the 3 month period ending September 30th, our domestic cancer test orders increased to 475, more than double the test volume generated in the previous Quarter. Factoring in bulk discounts, the median selling price per test was about $125. We anticipate further growth in the current and subsequent quarters. Further information about OneTest™ may be found here.

OneTest now available in China

On September 23, we executed our first OneTest™ subscription agreement in China with the Beijing Canaan Clinic. This clinic is affiliated with and partially owned by the Beijing University Cancer Hospital, one of the most prestigious in China.

Canaan Clinic, http://www.jncancer.com/, typical of a group of private health check centers emerging throughout China, will be offering the OneTest™

analytical software to its existing clients and using our distinctive A.I. powered technology to help attract new clients. Subscription agreements with other private clinics in China are expected over the next 6-9 months.

OneTest Presented at Elite Cancer Detection Scientific Meeting

In September we were invited to present the scientific basis of OneTest to the National Cancer Institute's (NCI) Early Detection Research Network (EDRN), the premier gathering of leading cancer screening scientists and clinicians in the U.S. A copy of the poster we presented can be downloaded here . Of more than 75 posters presented, ours was one of only 11 invited to also make an oral presentation.

‌

New Sales Leadership Installed

Last month, 20/20 retained Ron Baker as Director of U.S. Sales . Ron has more than three decades of experience in leading sales and marketing efforts for oncology and diagnostics companies. He has consistent achievement of revenue goals in a Sales and Marketing Leadership role with Fortune 500 and start-up companies including P/L responsibilities. Ron has extensive sales, marketing, operational and customer-centric experience in the CRO, Clinical, Diagnostic and Research segments of the Pharmaceutical and Biotechnology industry, with special emphasis in Oncology.

Working with Ron will be David Lees who was promoted last month from Virginia regional Sales Representative to National Sales Manager .

Recruit Your Healthcare Provider & Get Free Yearly Cancer Screening for Life

Because of our success last year with equity crowdfunding under the new Regulation A+, 20/20 is fortunate to have over 4,000 shareholders throughout the U.S. and around the world. We are now seeking to leverage this substantial shareholder base to help grow test adoption worldwide.

We invite all shareholders to introduce OneTest to their doctor or medical screening provider. (We will provide you with a short hand-out to present to your doctor that summarizes the test's clinical performance and value.) If your introduction results in the healthcare provider routinely offering this test to patients, you will be entitled to a yearly OneTest™ for the rest of your life at no cost. (Available to US shareholders only)

For details, please contact Careen at ccarlton@2020gene.com or call 240-453-6339 x 108

Did you miss 20/20's Annual Meeting over the summer? Click here, then and download

the presentation

Our previous Quarterly Reports may be downloaded here:

Financial Reports

In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those interested in obtaining copies of recently SEC filed Financial Statements should contact DavidK@2020gene.com

Regulation A

20/20 GeneSystems is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. The Final Offering Circular that forms a part of the Offering Statement may be downloaded here: https://www.seedinvest.com/2020.genesystems

Investing in an initial public offering under Regulation A is subject to unique risks, tolerance for volatility, and potential loss of principal, that customers should be aware of prior to making an investment decision. For more information about Regulation A offerings, including the unique risks associated with these types of offerings, please click on the SEC's Reg. A Investor Bulletin .

Forward-Looking Statements

Some of the statements in this document including statements regarding a future offering of the Company's securities under Regulation A, the potential success of any such offering, and the Company's ability to successfully sell and commercialize its cancer diagnostic products, constitute forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends, and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "plan", "potential", "should", "will" and "would" or the negatives of these terms or other comparable terminology.

You should not place undue reliance on forward looking statements. The cautionary statements set forth in the Form 1-A with the SEC in March 2018, including in "Risk Factors" and elsewhere therein, identify important factors which you should consider in evaluating our forward-looking statements.

Although the forward-looking statements in this document are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements, or outcomes. No assurance can be made that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law.